Literature DB >> 1280104

Evolutionary conservation of the dystrophin central rod domain.

T G Sherratt1, T Vulliamy, P N Strong.   

Abstract

Dystrophin cDNA fragments encoding the C-terminal repeats of the central rod region have been expressed as fusion proteins. The polyclonal antisera raised to the purified fusion proteins have been characterized and neither antiserum cross-reacted with dystrophin-related protein. Antisera detected dystrophin with molecular mass close to that of the human in all terrestrial vertebrates and amphibia studied. Experiments with antisera to the N-terminal region of the dystrophin rod confirmed that epitopes to the rod region were conserved during this evolutionary period and the length of this domain remained unaltered.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280104      PMCID: PMC1133072          DOI: 10.1042/bj2870755

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  24 in total

1.  Very mild muscular dystrophy associated with the deletion of 46% of dystrophin.

Authors:  S B England; L V Nicholson; M A Johnson; S M Forrest; D R Love; E E Zubrzycka-Gaarn; D E Bulman; J B Harris; K E Davies
Journal:  Nature       Date:  1990-01-11       Impact factor: 49.962

2.  Dystrophin and nebulin in the muscular dystrophies.

Authors:  K Patel; T Voit; M J Dunn; P N Strong; V Dubowitz
Journal:  J Neurol Sci       Date:  1988-11       Impact factor: 3.181

3.  Diagnostic needle muscle biopsy. A practical and reliable alternative to open biopsy.

Authors:  J Z Heckmatt; A Moosa; C Hutson; C A Maunder-Sewry; V Dubowitz
Journal:  Arch Dis Child       Date:  1984-06       Impact factor: 3.791

4.  Dystrophin: the protein product of the Duchenne muscular dystrophy locus.

Authors:  E P Hoffman; R H Brown; L M Kunkel
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

5.  Tissue distribution of the dystrophin-related gene product and expression in the mdx and dy mouse.

Authors:  D R Love; G E Morris; J M Ellis; U Fairbrother; R F Marsden; J F Bloomfield; Y H Edwards; C P Slater; D J Parry; K E Davies
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

6.  An autosomal transcript in skeletal muscle with homology to dystrophin.

Authors:  D R Love; D F Hill; G Dickson; N K Spurr; B C Byth; R F Marsden; F S Walsh; Y H Edwards; K E Davies
Journal:  Nature       Date:  1989-05-04       Impact factor: 49.962

7.  The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein.

Authors:  M Koenig; A P Monaco; L M Kunkel
Journal:  Cell       Date:  1988-04-22       Impact factor: 41.582

8.  Alternative splicing of human dystrophin mRNA generates isoforms at the carboxy terminus.

Authors:  C A Feener; M Koenig; L M Kunkel
Journal:  Nature       Date:  1989-04-06       Impact factor: 49.962

9.  Differentiation of Duchenne and Becker muscular dystrophy phenotypes with amino- and carboxy-terminal antisera specific for dystrophin.

Authors:  D E Bulman; E G Murphy; E E Zubrzycka-Gaarn; R G Worton; P N Ray
Journal:  Am J Hum Genet       Date:  1991-02       Impact factor: 11.025

10.  Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies.

Authors:  A H Beggs; E P Hoffman; J R Snyder; K Arahata; L Specht; F Shapiro; C Angelini; H Sugita; L M Kunkel
Journal:  Am J Hum Genet       Date:  1991-07       Impact factor: 11.025

View more
  8 in total

1.  Genetic correction of dystrophin deficiency and skeletal muscle remodeling in adult MDX mouse via transplantation of retroviral producer cells.

Authors:  A Fassati; D J Wells; P A Sgro Serpente; F S Walsh; S C Brown; P N Strong; G Dickson
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

2.  Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice.

Authors:  Taeyoung Koo; Alberto Malerba; Takis Athanasopoulos; Capucine Trollet; Luisa Boldrin; Arnaud Ferry; Linda Popplewell; Helen Foster; Keith Foster; George Dickson
Journal:  Hum Gene Ther       Date:  2011-05-25       Impact factor: 5.695

3.  A novel point mutation (G-1 to T) in a 5' splice donor site of intron 13 of the dystrophin gene results in exon skipping and is responsible for Becker muscular dystrophy.

Authors:  Y Hagiwara; H Nishio; Y Kitoh; Y Takeshima; N Narita; H Wada; M Yokoyama; H Nakamura; M Matsuo
Journal:  Am J Hum Genet       Date:  1994-01       Impact factor: 11.025

4.  Exon skipping and translation in patients with frameshift deletions in the dystrophin gene.

Authors:  T G Sherratt; T Vulliamy; V Dubowitz; C A Sewry; P N Strong
Journal:  Am J Hum Genet       Date:  1993-11       Impact factor: 11.025

5.  Deletions in the 5' region of dystrophin and resulting phenotypes.

Authors:  F Muntoni; P Gobbi; C Sewry; T Sherratt; J Taylor; S K Sandhu; S Abbs; R Roberts; S V Hodgson; M Bobrow
Journal:  J Med Genet       Date:  1994-11       Impact factor: 6.318

6.  Assignment of laminin heavy chains using the lectin Ricinus communis agglutinin-1.

Authors:  J D Wadsworth; A Okuno; P N Strong
Journal:  Biochem J       Date:  1993-10-15       Impact factor: 3.857

7.  Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion.

Authors:  Q L Lu; G E Morris; S D Wilton; T Ly; O V Artem'yeva; P Strong; T A Partridge
Journal:  J Cell Biol       Date:  2000-03-06       Impact factor: 10.539

8.  Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy.

Authors:  Alberto Malerba; Jagjeet K Kang; Graham McClorey; Amer F Saleh; Linda Popplewell; Michael J Gait; Matthew Ja Wood; George Dickson
Journal:  Mol Ther Nucleic Acids       Date:  2012-12-18       Impact factor: 10.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.